胃食管结合部腺癌中 PET/CT 的作用如何？

Is there a role for PET/CT with esophagogastric junction adenocarcinoma?

机构信息

From the *Department of Nuclear Medicine, Hospital Clínic, Barcelona, Spain; †Department of Nuclear Medicine, Santa Maria della Misericordia Hospital, Rovigo, Italy; ‡Department of Medical Oncology, §Endoscopy Unit, and ∥Department of Radiology, Hospital Clínic, Barcelona, Spain; and ¶Department of Radiology, University of Southern California, Los Angeles, CA.

出版信息

Clin Nucl Med. 2015 Mar;40(3):e201-7. doi: 10.1097/RLU.0000000000000661.

DOI:10.1097/RLU.0000000000000661

PMID:25546207

Abstract

The value of 18F-FDG PET/CT in the initial diagnosis and in the locoregional staging of esophagogastric junction adenocarcinoma is not fully established. However, 18F-FDG PET/CT is widely accepted as the best modality for identification of suspected metastases in staging of the disease. Results published in the literature suggest that 18F-FDG PET/CT may provide useful information for response assessment to neoadjuvancy and to differentiate responding and nonresponding tumors. We review the potential role of 18F-FDG PET/CT imaging in staging, restaging, and prognostic value after chemoradiation therapy in esophagogastric junction adenocarcinoma.

摘要

18F-FDG PET/CT 在胃食管结合部腺癌的初始诊断和局部区域分期中的价值尚未完全确立。然而，18F-FDG PET/CT 被广泛认为是诊断疾病分期中可疑转移的最佳方式。文献中的研究结果表明，18F-FDG PET/CT 可能为新辅助治疗的反应评估和区分反应性和非反应性肿瘤提供有用的信息。我们回顾了 18F-FDG PET/CT 成像在胃食管结合部腺癌的分期、再分期和放化疗后预后价值中的潜在作用。